Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
119.90
+0.06 (+0.05%)
Streaming Delayed Price
Updated: 3:01 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
522,535
Open
120.04
Bid (Size)
119.88 (2)
Ask (Size)
119.90 (2)
Prev. Close
119.84
Today's Range
119.67 - 120.67
52wk Range
92.19 - 119.91
Shares Outstanding
N/A
Dividend Yield
2.89%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Today 9:33 EDT
Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate ASCVD risk patients, as the company continues to explore its potential in...
Via
Benzinga
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Today 6:58 EDT
From
Lindy Biosciences
Via
Business Wire
Performance
YTD
+18.71%
+18.71%
1 Month
+8.34%
+8.34%
3 Month
+20.28%
+20.28%
6 Month
+16.24%
+16.24%
1 Year
+17.16%
+17.16%
More News
Read More
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
August 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
August 26, 2024
Via
Benzinga
Uncovering Dividend Opportunities with NYSE:NVS.
August 23, 2024
Via
Chartmill
Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
August 07, 2024
Via
Chartmill
Why NYSE:NVS is a Top Pick for Dividend Investors.
August 02, 2024
Via
Chartmill
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
August 18, 2024
Via
The Motley Fool
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
August 13, 2024
Via
Benzinga
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
August 12, 2024
Via
Newsfile
Exposures
Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
Novartis Reports Near 40% Margin In Q2; Shares Slide
July 18, 2024
Via
Investor's Business Daily
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
August 08, 2024
Via
Benzinga
Exposures
Product Safety
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
Via
FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From
Arvinas Inc.
Via
GlobeNewswire
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
July 23, 2024
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
Via
Investor's Business Daily
Pharma Leader Beats on Earnings, But Shares Fall
July 19, 2024
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
July 18, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
July 18, 2024
Via
The Motley Fool
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
July 18, 2024
Via
Benzinga
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
July 18, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.